These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB. J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033 [Abstract] [Full Text] [Related]
4. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y. Biomaterials; 2016 Dec; 111():55-65. PubMed ID: 27723556 [Abstract] [Full Text] [Related]
5. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity. Xie Y, Bai O, Zhang H, Li W, Xiang J. Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793 [Abstract] [Full Text] [Related]
7. Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle. Yan W, Jiang S. Trends Cancer; 2020 Jun; 6(6):506-517. PubMed ID: 32460004 [Abstract] [Full Text] [Related]
8. Exosomal cancer immunotherapy is independent of MHC molecules on exosomes. Hiltbrunner S, Larssen P, Eldh M, Martinez-Bravo MJ, Wagner AK, Karlsson MC, Gabrielsson S. Oncotarget; 2016 Jun 21; 7(25):38707-38717. PubMed ID: 27231849 [Abstract] [Full Text] [Related]
9. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Cho JA, Yeo DJ, Son HY, Kim HW, Jung DS, Ko JK, Koh JS, Kim YN, Kim CW. Int J Cancer; 2005 Apr 20; 114(4):613-22. PubMed ID: 15609328 [Abstract] [Full Text] [Related]
15. Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing. Ouchi Y, Patil A, Tamura Y, Nishimasu H, Negishi A, Paul SK, Takemura N, Satoh T, Kimura Y, Kurachi M, Nureki O, Nakai K, Kiyono H, Uematsu S. Int Immunol; 2018 Apr 03; 30(4):141-154. PubMed ID: 29617862 [Abstract] [Full Text] [Related]
17. Personalized medicine and back-allogeneic exosomes for cancer immunotherapy. Samuel M, Gabrielsson S. J Intern Med; 2021 Feb 03; 289(2):138-146. PubMed ID: 31359504 [Abstract] [Full Text] [Related]
18. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity. Xie Y, Zhang H, Li W, Deng Y, Munegowda MA, Chibbar R, Qureshi M, Xiang J. J Immunol; 2010 Nov 01; 185(9):5268-78. PubMed ID: 20881190 [Abstract] [Full Text] [Related]
19. Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8⁺ cell-derived exosomes. Nazimek K, Ptak W, Nowak B, Ptak M, Askenase PW, Bryniarski K. Immunology; 2015 Sep 01; 146(1):23-32. PubMed ID: 25808106 [Abstract] [Full Text] [Related]
20. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson MC, Näslund TI, Gabrielsson S. Cancer Res; 2013 Jul 01; 73(13):3865-76. PubMed ID: 23658368 [Abstract] [Full Text] [Related] Page: [Next] [New Search]